Selective inhibition of the inducible isoform of I G/H synthase (cydooxygenase-2; COX2; EC 1.14.99.1) can be achieved with compounds of the general form of aryl methyl sulfonyls and aryl methyl sulfam . DuP 697 and NS-398 are rep tive examples of these compounds. Both inhibit the
itutive (COXi) and inducible (COX2) isoforms ofthe enzyme with equal potency shortly after i, but their potencies increase with time for COX2 selectively. This time-dependent inhibition follows firt-order kinetics, and the rate constant for inactivation of COX2 is dose dennt for both compounds. Kinetic analysis allows us to determine K5 and Ed (the mx l rate of inactivation) for each inhibitor. The potency of both compounds I substrate concentration dependent, as expected for time-dependent competitive inhibitors. COX2 that has been incubated with these inhibitors, and then extensively dialyzed against buffer, shows no recovery ofenzyme activit, while complete recovery of activity is seen for COX1.
Thus, these hibitors freersby inactivate COX2 with time, while showing minimal reversible inhibition of COX1. We isolated these inhibitors after long incubation with excess enzyme and subseqOent denaturatin of the enzyme. Both inhibitors showed no loss of potency resulting from interactions with COX2, _ that inhibition is not mediated by covalent modfctIon of the enzyme. These data suggest that binding of these inhibtrs to COX2 induces a slow str l tranition of the enzyme that results In its selective inactivation.
Prostaglandins are mediators ofpain, fever, and other symptoms associated with inflammation. Their biosynthesis is rate limited by the initial conversion of arachidonic acid to prostaglandin G, and this to prostaglandin H, by a single enzyme, prostaglandin G/H synthase (EC 1.14.99.1; cyclooxygenase; COX). Nonsteroidal anti-inflammatory drugs (NSAIDs) elicit their therapeutic effects by inhibition of prostaglandin synthesis by this enzyme (1) . The typical side effects of NSAID treatment, such as gastric and renal ulceration, are also due to inhibition of this enzyme within the mucosal lining of the gastrointestinal tract and kidney (1, 2) .
Recently it was reported that two isoforms of this enzyme exist in mammalian and avian species and that one of these isoforms, COX2, is induced in response to inflammatory stimuli (3, 4) . The other isoform, COX1, is constitutively expressed and is the major isoform of gastrointestinal tissue (2, 5) . It is thought, therefore, that the anti-inflammatory effects of NSAIDs are due to inhibition of the inducible isoform COX2, while many of the unwanted side effects of these drugs result from inhibition of COX1. Selective inhibition of COX2 activity would thus provide a significant improvement over current methods of therapeutic intervention for inflammatory diseases, such as arthritis.
The cDNA and amino acid sequences of both human isoforms have been reported (6, 7) . The two enzymes share -60%o amino acid sequence identity. Both catalyze the same cyclooxygenase and peroxidase activities, utlizing a noncovalently associated heme cofactor, and both are glycosylated to similar extents (8) . These similarities notwithstanding, we and others have found that the two isoforms can be selectively inhibited by certain compounds (9, 10) . Of particular interest are compounds that selectively inhibit COX2 with high potency while displaying weak potency against COX1. We have found that an experimental compound, DuP 697 [5-bromo-2-(4-fluorophenyl)-344-methylsulfonylphenyl)thiopheneJ, demonstrates these properties in vitro (unpublished results). At the same time, Futaki et al. (10) have reported that another experimental drug, NS-398 {N-[2-(cyclohexyloxy)4nitrophenyl]methanesulfonamide}, is also a selective inhibitor of COX2. Both DuP 697 (11) and NS-398 (12) demonstrated good potency as anti-inflammatories, but essentially no ulcerogenicity, in in vivo animal models. These results further strengthen the hypothesis that a selective inhibitor of COX2 would provide an effective treatment for inflammation without the typical gastric and renal liabilities of current NSAIDs.
In this report we have analyzed the mechanism by which both of these compounds elicit their selective effects on COX2. We find that these compounds share a common mechanism of action: they both induce a slow structural transition of the enzyme upon binding that results in significant and irreversible inhibition of COX2. While these compounds bind to COX1 and display modest inhibition, they do not induce the same structural transition in this isozyme. It is this structural transition that leads to the selective inhibition displayed by these compounds.
MATERIALS AND METHODS
Recombinant human COX1 and COX2 were expressed in insect cells and purified as will be described elsewhere (H. George, R.A.C., M.C., S.P., L. D'Angelo, M. Lischwe, G. Davis, and J.M.T., unpublished work). Ovine COX1 was purchased from Cayman Chemicals (Ann Arbor, MI). All of the COX1 data presented here are for the ovine isozyme. In all cases similar results were subsequently obtained with the recombinant human COX1. DuP 697 and NS-398 were synthesized by the Medical Chemistry group of DuPont Merck Research Laboratories. These compounds were stored as dry powders and dissolved in dimethyl sulfoxide (DMSO) to prepare a concentrated stock solution on the day of the experiments. Tween 20 was purchased from Pierce. Gelatin, hematin, and NNN',N'-tetramethyl-p-phenylenediamine (TMPD) were purchased from Sigma. All other reagents were Abbreviations: COX, cyclooxygenase; NSAID, nonsteroidal antiinflammatory drug; DMSO, dimethyl sulfoxide; TMPD, N,N,N',N'-tetramethyl-p-phenylenediamine.
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Enzyme activity was measured by following the oxidation of TMPD at 600 nm in a microtiter plate format. Enzyme (200 units) was incubated at 250C with the indicated concentration of inhibitor in enzyme reaction buffer (100 mM Tris-maleate buffer, pH 6.5, containing 0.1% Tween-20, gelatin at 1 mg/ml, 3 AM hematin, and 100 puM TMPD). One unit of enzyme activity is defined as the amount of enzyme required to cause a change in TMPD absorbance at 600 nm of 0.001 per min. Inhibitors were added from stock solutions prepared in DMSO so that the final DMSO concentration was always 10%o of the final sample volume. After the indicated preincubation time, the enzymatic reaction was initiated with 100 ,uM arachidonic acid (saturating conditions; Km = 13 uM), and the initial velocity ofthe reaction was measured for <21 sec by following the oxidation of TMPD at 600 nm. The velocities observed at different inhibitor concentrations were divided by the velocity observed for enzyme samples preincubated for the same time with 10%6 (vol/vol) inhibitor-free DMSO, and this ratio was multiplied by 100 to yield percent control activity.
Competition experiments between the inhibitors and substrate were performed at a fixed concentration of inhibitor (30 pM) and varying amounts of enzyme substrate between 10 and 200 uM. For these experiments the inhibitor and substrate were combined and added simultaneously to the enzyme sample. The initial velocity was measured as described above. The rate constant for inhibition was determined from the effect of the inhibitor on the initial velocity of the reaction at each substrate concentration, using equation A10 of Tian and Tsou (13) .
The reversibility of inactivation of the enzymes by these inhibitors was assessed by microdialysis. Enzyme (2000 units) was incubated with the various concentrations of inhibitor in a total volume of 200 Ad of enzyme reaction buffer for 10 min at 40C. After incubation the samples were loaded into microdialysis chambers (14) with a 12-kDa molecular mass cutoff membrane and dialyzed against 500 ml of inhibitor-free reaction buffer for 5 hr. After dialysis the remaining enzymatic activity was measured as described above. Control activity was measured by treating separate samples of COXi and COX2 as described here, but incubating with inhibitor-free DMSO, rather than inhibitor, prior to dialysis.
Recovery of inhibitor potency after incubation with COXi or COX2 was measured as follows. Inhibitor (1 pM) was incubated with 2 pM purified COX2, 2 pM purified COX1, or no protein for 40 min at 250C. After incubation the samples were treated with 4 vol of 1:1 (vol/vol) methanol/acetonitrile to denature the enzymes. The solutions were loaded into Microcon 30 microconcentrators (Amicon) and centrifuged for 5 min in a microcentrifuge. The protein-free filtrate was dried completely in a Speed Vac concentrator (Savant) to remove the volatile denaturants and solvent. The dried material was resuspended in DMSO to an apparent concentration of 1 mM. Various amounts of this stock solution were added to fresh samples of COX2 (200 units in enzyme reaction buffer) to yield the final inhibitor concentrations indicated. The fresh enzyme was incubated with inhibitor for 2 min at 250C before the enzyme reaction was initiated with 100 pM arachidonic acid. for DuP 697 and NS-398, respectively, under these conditions. When, however, the enzymes are preincubated with these inhibitors for 5 min prior to substrate addition, one observes a dramatic enhancement of inhibitor potency selectively for the COX2 isoform for both inhibitors, so that the selectivity for COX2 increased to 10.2 and 10.7 for DuP 697 and NS-398, respectively. To investigate this observation further we measured the residual activity of both isozymes after various periods of time in contact with these two compounds (Fig. 1) . For both DuP 697 and NS-398 one observes a rapid diminution of COX2 enzymatic activity with preincubation time, the rate of diminution increasing with increasing concentration of inhibitor. In contrast to these results, however, only modest, if any, time-dependent loss of enzymatic activity is observed for COXi with these inhibitors.
RESULTS AND DISCUSSION
All of the data presented in Fig. 1 can be fit well to a series of first-order decay curves, from which one can extract estimates of the rate constant for inactivation of the enzymes (kobs) by various concentrations of these inhibitors. For time-dependent irreversible inhibitors the value of k" is expected to increase over a certain range of inhibitor concentration and then exhibit saturation at higher concentrations of inhibitor (15) . Kitz and Wilson (15) have shown that the dependence of kob, on inhibitor concentration for a time-dependent irreversible inhibitor is described by a rectangular hyperbola from which the values of kie, the maximal rate constant for inactivation of the enzyme by the inhibitor, and KI, the apparent concentration of inhibitor displaying half-maximal rate of inactivation, can be extracted. As illustrated in Fig. 2 , the time-dependent inhibition of COX2 by either DuP 697 or NS-398 is well described by this equation, allowing us to estimate values of kijt and K1 for both inhibitors: the kint values estimated from these fits were 0.017 and 0.049 sec-1, and the Ki values were 2.19 and 11.50 &M for DuP 697 and NS-398, respectively. We see from this analysis that NS-398 displays a slightly faster maximal rate of inactivation of COX2 than does DuP 697. This is compensated for, however, by the fact that DuP 697 displays slightly greater affinity (KO for COX2. The overall potency of a time-dependent inhibitor of this type is best estimated from the second-order rate constant derived by dividing kin1 by K1 (15, 16) . By this measure the two inhibitors studied here are quite comparable in their ability to inhibit COX2: 7 .76 x 10-3 and 4.26 x 10-3 sec'1-AM'1 for DuP 697 and NS-398, respectively. The time dependence displayed by these inhibitors for COXi was so modest that we could not perform this same type of kinetic analysis for this isozyme.
The rectangular hyperbolic fit used for the data in Fig. 2 is reminiscent of the Michaelis-Menten equation for enzyme velocity as a function of substrate concentration. A common practice among enzymologists is to linearize data of this type by using double-reciprocal plots (17) . Plots of 1/k",. as a function of 1/[I] for both NS-398 and DuP 697 are indeed linear, but intersect the y axis at values of 1/kobs greater than zero (data not shown). Kitz and Wilson (15) have shown that a nonzero y intercept for such plots is an indication that the enzyme inactivation event is preceded by an earlier event, this usually being equated with initial inhibitor binding to the enzyme. Thus for both NS-398 and DuP 697 the present data indicated that the inhibitors bind to COX2 and elicit some modest inhibition by binding, but then subsequent to binding, a separate event occurs, leading to potent inactivation of the enzyme. In the case of COX1, inhibitor binding does not appear to be followed by this inactivating event. That timedependent inactivation of COX2 is preceded by a distinct binding event is also reflected in the first-order fits of the time-dependency data shown in Fig. 1 . We note, especially in Inhibitor concentrations over the range of 1-300 pM were tested, each concentration being indicated by a different character. Error bars indicate the standard deviations associated with each data point. The curves drawn through the data are nonlinear least-squares best fits to a first-order decay process. Nonlinear least-squares fits throughout this paper were performed by using the Marquardt-Levenberg algorithm within the graphics program Kaleidagraph (Abelbeck Software). the case of DuP 697, that the first-order fits at various inhibitor concentrations do not intersect at 100% control activity at zero preincubation time. Rather, the data indicated 0.015 The curves drawn through the data here represent the nonlinear least-squares fits to a rectangular hyperbolic function (15) .
that there is some diffusion-limited inhibition of the enzyme (i.e., inhibitor binding) that precedes the slower timedependent inhibition discussed above. As illustrated in Fig.  1 , this diffusion-limited inhibition is similar for COXi and COX2 with both NS-398 and DuP 697. Thus these inhibitors appear to bind with similar affinity to both isozymes; the selectivity for COX2 inhibition displayed by these compounds is therefore associated with their ability to elicit a subsequent inactivation of COX2 but not COX1. Like simple reversible enzyme inhibitors, time-dependent inhibitors can be competitive, uncompetitive, or noncompetitive with respect to substrate binding by the enzyme (13) . To determine the mode of interaction of NS-398 and DuP 697 with COX2, we studied the effects of substrate (arachidonic acid) concentration on the observed rate ofinactivation ofthe enzyme by a fixed concentration of inhibitor (30 uM). For these studies inhibitor and substrate were added simultaneously to the enzyme, and the rate of inactivation was determined from the diminution of initial enzyme velocity caused by the inhibitor (13) . For competitive time-dependent inhibition, one expects the rate of enzyme inactivation by the inhibitor to wane with increasing substrate concentration (13) . Fig. 3 illustrates the effects of increasing substrate concentration on the rate of COX2 inactivation for DuP 697 (Fig. 3A) and NS-398 (Fig. 3B ). The curves drawn through the data points are the nonlinear least-squares best fits to the equation for time-dependent competitive inhibition, and they demonstrate clearly that both DuP 697 and NS-398 act as competitive inhibitors. Thus for both of these inhibitors it appears that binding to the active site (i.e., substrate binding site) of COX2 is a prerequisite for time-dependent inhibition. While coadministration of inhibitor and substrate demonstrates the competitive nature of these compounds, we find that when COX2 is preincubated with either inhibitor for an extended time (10 min or more) the ability of the substrate to compete with inhibitor for the enzyme active site is signifi- -398 (B) . The curves drawn through the data represent the nonlinear least-squares fits to the expected behavior for a competitive inhibitor as described in ref. 13. cantly diminished (data not shown). This result suggests either that the mode of inhibition for these compounds changes with time or that the inactivation step associated with time-dependent inhibition is irreversible.
Whatever the molecular event is that leads to selective inhibition of COX2 by these compounds, it appears to be irreversible. We determined this by incubating both isozymes with various concentrations of either NS-398 or DuP 697 for an extended period of time (10 min) and then dialyzing the enzyme extensively against inhibitor-free buffer. After dialysis the activities of the enzyme samples were determined and compared to those of control samples that were similarly dialyzed without having been treated with inhibitor. As illustrated in Fig. 4 , after dialysis COX2 still displayed inhibition that depended on the concentration of inhibitor presented to the enzyme prior to dialysis. For COX1, however, all of the inhibition elicited by these compounds was lost after dialysis.
The data presented above indicate that DuP 697 and NS-398 derive their selectivity for inhibition of COX2 by binding to the enzyme active site and subsequently causing a slow irreversible event that leads to significant inactivation of the enzyme. With COXi also these two inhibitors appear to bind to the enzyme active site, but they fail to induce the time-dependent event that leads to potent inactivation. What type of postbinding event might be occurring selectively for COX2 with these compounds? Two schemes come to mind that could explain our data. In the first scheme, dependent chemical modifying agents are known. In fact, the most commonly used NSAID, aspirin, acts by inhibiting COX through such a chemical modification event, acetylation of active site residue serine 530 (18) . An alternative explanation for the data is provided by Scheme II, < k~kon k Adnm Scheme II where inhibitor binding evokes a conformational transition of the enzyme leading to significantly tighter (for all practical purposes irreversible) binding of the inhibitor to the enzyme. There is a precedent for this type of time-dependent inactivation ofenzymes as well. For example, Kulmacz and Lands (19) have shown that indomethacin, a time-dependent inactivator of COX1, induces a conformational change in the enzyme that leads to essentially irreversible binding without any chemical modification of the enzyme or inhibitor.
In Scheme I we note that chemical modification of the enzyme by the inhibitor leads to transfer of the pharmacophoric portion (I in our illustration) ofthe inhibitory molecule to the enzyme. If one were to subsequently recover the by-product of this chemical reaction (X in our illustration) one would expect that this by-product would have lost the ability to-inhibit other molecules ofenzyme. With this in mind we treated COX2 with a substoichemometric amount of DuP 697 or NS-398 (conditions where all of the inhibitor molecules should interact with enzyme). After incubation (40 min) the enzyme was denatured with methanol/acetonitrile, and the inhibitor or by-product was recovered after removal of denatured enzyme and the volatile denaturants. This material was then used to prepare a stock solution of compound that was tested for its ability to inhibit the enzymatic activity of fresh samples of COX2. Fig. 5 illustrates the results of these experiments for DuP 697 and NS-398. For both compounds the inhibition curves observed after reaction with COX2 are, within experimental error, indistinguishable from those for control samples that were not pretreated with enzyme or were pretreated with COXi rather than COX2. Thus for both compounds prolonged interaction with COX2 did not lead to loss of the pharmacophoric portion of the molecules. These data strongly suggest that these compounds elicit their selective inhibition of COX2 by inducing a structural transition of the enzyme that leads to very tight association with the inhibitor. In our illustration of Scheme H we have represented this structural transition as a global change in enzyme shape in going from form E to E'. We note that our data do not necessarily indicate such a large-scale structural transition ofthe enzyme. A much more subtle change in the vicinity of the active site would suffice to explain the present results.
The data presented here provide significant insights into the mode of potent and selective inactivation of the inducible isoform, COX2, by DuP 697 and NS-398. Despite their dissimilar chemical structures, both these compounds appear to inhibit COX2 selectively by a common mechanism of action. Use of this mechanistic information may provide a means of developing even more effective and selective inhibitors for this isozyme, ultimately leading to significant therapeutic benefits for patients suffering from inflammatory diseases.
